Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Developing Individualized Strategies to Prevent Nausea and Vomiting.

Next Previous
Trial Profile

Developing Individualized Strategies to Prevent Nausea and Vomiting.

Status: Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 17 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aprepitant (Primary) ; Lorazepam (Primary) ; Ondansetron (Primary)
  • Indications Postoperative nausea and vomiting
  • Focus Pharmacogenomic; Therapeutic Use

Most Recent Events

  • 13 Nov 2013 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
  • 08 Feb 2012 Planned initiation date changed from 1 Dec 2011 to 1 Apr 2012 as reported by ClinicalTrials.gov.
  • 15 Jul 2011 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top